IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.
Open Access
- 1 May 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 144 (9) , 3630-3636
- https://doi.org/10.4049/jimmunol.144.9.3630
Abstract
We performed functional assays on polymorphonuclear (PMN) leukocytes from 21 patients with advanced cancers, before, during, and after IL-2 administration. Of these, 19 were treated with high dose bolus IL-2 infusions (10(5) U/kg every 8 h) and 2 patients received low dose continuous infusions of IL-2 (250 U/kg/h). Five of six patients studied after IL-2 therapy had a decrease in their PMN chemotactic response to FMLP after bolus IL-2 (mean 8 doses) or, after the 4th day of continuous infusion IL-2 (pre-IL-2 values of 82% +/- 17% to 45% +/- 1% post-IL-2, p2 less than 0.004) compared with normal control values. In 8 of 10 patients studied, PMN capacity to oxidize intracellular dichlorofluorescein dye, an indirect measurement of O2- production in response to PMA stimulation, decreased after IL-2 administration (pre-IL-2 mean dichlorofluorescein oxidation (by channel number) 243 +/- 128 vs 3-day post-IL-2 87 +/- 86, p2 less than 0.02). Furthermore, a marked decrease in Fc gamma R III (Leu-11, CD16) expression was observed in 12/13 patients' PMN studied after IL-2 therapy (mean percent of PMN population with positive FcR expression was 81.1 +/- 15.4% pre-IL-2 which decreased to 56.0 +/- 30.5% post-IL-2, p2 less than 0.001). Other PMN surface markers (My4, My7, ICAM-1, LFA1, LFA3, Mac1) did not change significantly. PMN-mediated antibody-dependent cellular cytotoxicity did not change after IL-2 therapy (only 4/15 patients demonstrated more than 50% reduction in antibody-dependent cellular cytotoxicity). PMN phagocytosis of Staphylococcus aureus was also not significantly altered by IL-2 administration in six patients studied (pre-IL-2, 99 +/- 17% vs 111 +/- 28% post-IL-2, p2 greater than 0.2). We conclude that the systemic administration of IL-2 by intermittent or continuous administration is associated with marked changes in PMN function and cell surface receptor expression. These alterations may contribute to the apparent increased susceptibility to bacterial infection observed in these patients.This publication has 19 references indexed in Scilit:
- Comparison of the effects of indomethacin, RHC80267 and R59022 on superoxide production by 1,oleoyl-2,acetyl glycerol and A23187 in human neutrophilsBritish Journal of Pharmacology, 1987
- High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findingsJAMA, 1986
- POLYMORPHONUCLEAR LEUKOCYTE HETEROGENEITY IN NEONATES AND ADULTS1986
- Stimulation of neutrophils by tumor necrosis factor.The Journal of Immunology, 1986
- Tumor necrosis factor provokes superoxide anion generation from neutrophilsBiochemical and Biophysical Research Communications, 1986
- In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.The Journal of Immunology, 1985
- Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.The Journal of Immunology, 1985
- Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies.The Journal of Experimental Medicine, 1984
- MODULATION OF PHAGOCYTOSIS AND BACTERICIDAL ACTIVITY OF HUMAN POLYMORPHONUCLEAR AND MONONUCLEAR PHAGOCYTES BY ANTIARTHRITIC AGENTS1983
- The effect of nonsteroidal anti-inflammatory agents on E. coli-induced inflammationImmunopharmacology, 1982